Patients
Tumors, thromboembolic, glaucoma, retinal degenerative disease
CARCINOMATOUS MENINGITIS, CENTRAL SEROUS RETINOPATHY, NEUROMUSCULAR DISORDERS, RETINAL VEIN OCCLUSION, TUMORS, GLAUCOMA, ONCOLOGY, EVENTS, INTRAOCULAR PRESSURE
Eligible patients were ≥ 18 years old with a histologically/cytologically documented, locally advanced or metastatic solid tumor; had received or been intolerant to all treatments known to confer clinical benefit; had ≥ 1 measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; had Eastern Cooperative Oncology Group (ECOG) performance status of 0−1; and had adequate organ function.Key exclusion criteria included clinically active central nervous system metastases and/or carcinomatous meningitis; thromboembolic or cerebrovascular events within ≤ 6 months; neuromuscular disorders associated with elevated creatine kinase; and certain ophthalmologic findings (intraocular pressure > 21 mmHg or uncontrolled glaucoma; current or history of central serous retinopathy or retinal vein occlusion; or retinal degenerative disease). Previous treatment with a MEK, ERK, or BRAF inhibitor was also an exclusion criterion.